Back to search

Democritus University of Thrace (DUTH)

Η επίδραση των νέων διαλυμάτων περιτοναϊκής κάθαρσης χαμηλής περιεκτικότητας σε προϊόντα διάσπασης γλυκόζης στην κλινική έκβαση των ασθενών που υποβάλλονται σε περιτοναϊκή κάθαρση

Abstract

dc:description

Background: The significance to preserve the peritoneal membrane integrity for peritoneal dialysis (PD) patients by using more biocompatible solutions (low in glucose degradation products-GDPs, without lactate as a buffer, without glucose and with normal pH) becomes increasingly more evident. Additionally the systemic effects of absorbed glucose degradation products (GDPs) contained within the conventional peritoneal dialysis solutions (cPDS) are largely unknown, while they appear to affect also cardiovascular function The aim of the present study was to evaluate the alteration in the concentrations of different dialysate markers CA125, (glygoprotein, as an indicator of mesothelial cell mass) Vascular Endothelial Growth Factor (VEGF,an angiogenic factor) Interleukin 6 (IL6, a possible marker of peritoneal inflammation) TGFb (marker of fibrosis) and Glyoxal (GDP, a glucose degradation product, toxic agent for the membrane) with the use of new bicarbonate-based less bioincompatible peritoneal dialysis solutions. Additionally we evaluate the possibility if the new bicarbonate-based less bioincompatible new peritoneal dialysis solutions (nPDS) ameliorate cardiac structural and functiomal status, as well as the peritoneal net ultrafiltration (UF) and residual renal function (RRF). Patients-Methods: This is a single centre, prospective cohort study of 12 stable CAPD patients (4 women , 8 men) mean age 71.3 ± of 6.01 years and mean PD duration 31.9 ± 21.33 months, treated with the usual conventional PD solutions (Medital Bieffe®, with increased GDPs, low ph and lactate as a buffer system). The patients changed for a six months period into biocompatible PD solutions (BicaVera, Fresenius®) and at the end of this time they returned into their previous schema of conventional solutions, for another six months. The dialysate markers of CA125, VEGF, IL6, TGFb and Glyoxal were repeatedly estimated at the beginning of the study (T0), after 6 months with the biocompatible solutions (T6) and at the end of study (T12), after the six months period using again the conventional PD solutions. All the samples were taken at the end of a 4 hour dwell of an exchange with PD solution 2.5% glucose. Additionally during the study period the Left Ventricle Ejection Fraction (EF), Left Ventricle End Systolic and Diastolic Diameter (LVESD , LVEDD), Left Ventricle Mass Index (LVMI), Glyoxal serum and peritoneal concentrations, net UF and 24 hour Urine volume were estimated at the beginning of the study in the middle and at the end of the study. Results: There was statistically significant difference between the Appearance Rate (AR) mean levels of dialysate markers at the beginning (T0) and in the middle of the study (T6) (for CA125 p=<0.0001, for VEGF p = 0.01, for IL6 p=0.0005, for Glyoxal p=<0.0001 and for TGFb p=0.004) as well as between the mean values in the middle (T6) and at the end of the evaluation period (T12) (for CA125 p=0.0058, for VEGF p=0.002, for IL6 p=0.004 for TGFb p=0.044 and for Glyoxal p=0.006031). On the other hand not any statistically significant difference was revealed between the T0 and T12 AR mean values ...

Degree

thesis:*
Grantor dc:publisher
Democritus University of Thrace (DUTH)
Year dc:date
2010

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Theodoridis, Marios
  • Θεοδωρίδης, Μάριος

Subjects

dc:subject × 16

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/23808

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Theodoridis, Marios; Θεοδωρίδης, Μάριος. Η επίδραση των νέων διαλυμάτων περιτοναϊκής κάθαρσης χαμηλής περιεκτικότητας σε προϊόντα διάσπασης γλυκόζης στην κλινική έκβαση των ασθενών που υποβάλλονται σε περιτοναϊκή κάθαρση. Democritus University of Thrace (DUTH), 2010. http://hdl.handle.net/10442/hedi/23808